Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

2016 ◽  
Vol 16 ◽  
pp. S96-S100 ◽  
Author(s):  
Carmen Fava ◽  
Giovanna Rege-Cambrin ◽  
Irene Dogliotti ◽  
Enrico Gottardi ◽  
Paola Berchialla ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Newly Diagnosed ◽  
Event Free Survival ◽  
Free Survival

scholarly journals Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

Cancer ◽  
2010 ◽  
Vol 117 (2) ◽  
pp. 327-335 ◽  
Author(s):  
Aref Al-Kali ◽  
Hagop Kantarjian ◽  
Jianqin Shan ◽  
Roland Bassett ◽  
Alfonso Quintás-Cardama ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Event Free Survival ◽  
Current Event ◽  
Free Survival ◽  
Tyrosine Kinase Inhibitor Therapy

scholarly journals Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Blood ◽  
2013 ◽  
Vol 121 (24) ◽  
pp. 4867-4874 ◽  
Author(s):  
Preetesh Jain ◽  
Hagop Kantarjian ◽  
Aziz Nazha ◽  
Susan O’Brien ◽  
Elias Jabbour ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Treatment Modality ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Early Response ◽  
Newly Diagnosed ◽  
Key Points

Key Points This analysis demonstrates the universality of the early response in CML, regardless of the treatment modality used. Factors correlating with poor cytogenetic responses at 3-mo assessment in a multivariate analysis across all 4 TKIs.

Sign in / Sign up

Export Citation Format

Share Document